Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Samil Pharmaceutical Co. Ltd. is a key player in the pharmaceutical industry, primarily focusing on the research, development, and distribution of a diverse range of medical products. The company's portfolio spans prescription medications, over-the-counter drugs, and various pharmaceutical solutions that serve multiple therapeutic areas. Samil Pharmaceutical is committed to advancing healthcare by leveraging innovation to create effective and safe medicinal products. Operating within a highly regulated sector, the company addresses critical healthcare needs and partners with both domestic and international healthcare providers to ensure accessibility and effectiveness of treatments. Samil's role in the market is significant, contributing to advancements in therapeutic solutions and improving patient outcomes. As part of the broader pharmaceutical ecosystem, the company collaborates with research institutions and other industry stakeholders to foster advancements in medical science and enhance the overall health of communities globally.
₩6,540.00
₩210.00 (-3.11%)
Live · 05:25 PM
The business is unprofitable at the operating level (-10.56% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 4.3% YoY. Margins deteriorated 10.6pp alongside, both lines moving the wrong way.
ROIC dropped from 0.03% to -5.63%, capital efficiency is deteriorating. Negative free cash flow of -₩6.95B. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩210.51B
▼ -4.3% YoY
Net Income (TTM)
-₩36.42B
▼ -515.8% YoY
Op. Margin
-11.98%
▼ -10.6pp YoY
ROIC
-5.63%
▼ -5.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩742M
▼ -130.1% YoY
Op. Cash Flow (TTM)
₩13.65B
▼ -78.5% YoY
Net Debt
₩157.61B
Cash & Equiv.
₩6.41B
3Y CAGR: +5.4%
Continue Research
Samil Pharmaceutical Co. (000520.XKRX) trades above a two-stage DCF intrinsic value of about KRW -6,537.27 per share, so at KRW 6,540.00 the stock looks overvalued (200.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Samil Pharmaceutical Co. scores 23/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW -6,537.27 per share for 000520.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW -4,902.95. At today's KRW 6,540.00, that puts the stock about 200.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Samil Pharmaceutical Co. scores 23 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -12.0% operating margin and a -5.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 000520.XKRX currently trades above its estimated intrinsic value and scores 23/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.